These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 25790076)
1. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. Chung-Delgado K; Guillen-Bravo S; Revilla-Montag A; Bernabe-Ortiz A PLoS One; 2015; 10(3):e0119332. PubMed ID: 25790076 [TBL] [Abstract][Full Text] [Related]
2. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Palacios E; Franke M; Muñoz M; Hurtado R; Dallman R; Chalco K; Guerra D; Mestanza L; Llaro K; Bonilla C; Sebastian J; Bayona J; Lygizos M; Anger H; Shin S Int J Tuberc Lung Dis; 2012; 16(3):348-54. PubMed ID: 22640448 [TBL] [Abstract][Full Text] [Related]
3. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Kliiman K; Altraja A Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treating multidrug-resistant tuberculosis. Resch SC; Salomon JA; Murray M; Weinstein MC PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403 [TBL] [Abstract][Full Text] [Related]
5. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. Kizito E; Musaazi J; Mutesasira K; Twinomugisha F; Namwanje H; Kiyemba T; Freitas Lopez DB; Nicholas NS; Nkolo A; Birabwa E; Dejene S; Zawedde-Muyanja S BMC Infect Dis; 2021 Mar; 21(1):292. PubMed ID: 33752637 [TBL] [Abstract][Full Text] [Related]
7. [Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014]. Wang JJ; Zhou ML; Chen C; Wu G; Zuo YP; Ren X; Chen Z; Wang WH Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1409-1413. PubMed ID: 31838813 [No Abstract] [Full Text] [Related]
9. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298 [TBL] [Abstract][Full Text] [Related]
10. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases. Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008 [TBL] [Abstract][Full Text] [Related]
11. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City. Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387 [TBL] [Abstract][Full Text] [Related]
12. HIV infection and multidrug-resistant tuberculosis: the perfect storm. Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830 [TBL] [Abstract][Full Text] [Related]
13. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131 [TBL] [Abstract][Full Text] [Related]
14. Survival of smear-positive multidrug resistant tuberculosis patients in Witbank, South Africa: A retrospective cohort study. Olaleye AO; Beke AK Infect Dis (Lond); 2016; 48(6):422-7. PubMed ID: 26954520 [TBL] [Abstract][Full Text] [Related]
15. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan. van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387 [TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. Pawar UM; Kundnani V; Agashe V; Nene A; Nene A Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244 [TBL] [Abstract][Full Text] [Related]
17. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Perez-Navarro LM; Restrepo BI; Fuentes-Dominguez FJ; Duggirala R; Morales-Romero J; López-Alvarenga JC; Comas I; Zenteno-Cuevas R Tuberculosis (Edinb); 2017 Mar; 103():83-91. PubMed ID: 28237037 [TBL] [Abstract][Full Text] [Related]
18. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda. Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845 [TBL] [Abstract][Full Text] [Related]